HPV Awareness Day

Despite the existence of prevention and screening tools, not everybody is aware of HPV (Human Papilloma Viruses), that it is associated with multiple types of cancer, and of the fact that HPV-related cancers can potentially be prevented. To help address the lack of knowledge and awareness, the International Papillomavirus Society (IPVS) coordinated the first International HPV Awareness Day on March 4, 2018

By Corie Leifer

Give Love Not HPV Campaign Coordinator

International Papillomavirus Society*

International HPV Awareness Day

 

HPV Affects Everyone

HPV Affects Everyone. Regardless of age, gender, race, or sexual orientation, the Human Papilloma Viruses (HPV) affects you, either directly or indirectly.

The most widespread and common sexually transmitted infections (STIs) in the world, there are many different types of HPV.

Studies show that more than 80% of sexually active men and women will acquire at least one HPV infection by the age of 45 years. As an infection with HPV may have no symptoms, it can go unnoticed.  Most HPV infections clear on their own, but some can lead to genital warts, and others can even lead to cancer.

HPV- Related Cancers

Cervical, anal, oral, penile, and other deadly cancers can all be related to HPV infection.  HPV is associated with 1 in every 20 cancer cases worldwide including almost all cervical and anal cancers, over a third of throat cancers and a quarter of mouth cancers. This accounts for approximately 640,000 new cancer diagnoses around the world every year. 80% of these diagnoses will be cervical cancer, but head and neck cancers continue to grow in number of cases at an alarming rate.

In 2006, HPV vaccines began to be introduced worldwide. These vaccines are both effective and safe for both boys and girls. Along with screening, vaccines provide the possibility to significantly reduce the number of newly diagnosed HPV-related cancers.

International HPV Awareness Day

Despite these alarming facts and the existence of prevention and screening tools, not everybody is aware of HPV, that it is associated with multiple types of cancer, and of the fact that HPV-related cancers can potentially be prevented.

To help address the lack of knowledge and awareness, the International Papillomavirus Society (IPVS) coordinated the first International HPV Awareness Day on March 4, 2018. Rather than a focus on a disease, this campaign focuses on HPV, which causes many diseases. This initiative was implemented in partnership with more than 80 organisations around world and will take place every March 4.

Campaign activities included press releases, workshops, conferences, races, rallies, interviews, print ads and conversations on a wide variety of social media.

On social media the #GiveLoveNotHPV  increased in the online conversation about HPV by over 5000% on March 2nd – March 5th and the campaign hashtag reached 2 million unique users on social media.

 

The International Papillomavirus Society (IPVS) is the leading global authority on human papillomaviruses (HPV). Our work facilitates the worldwide exchange of ideas, knowledge, and research about HPV and related diseases. IPVS actively promotes the translation of research results into new clinical applications and public health policies. IPVS inaugurated International HPV Awareness Day on March 4th 2018 as part of the organization’s commitment to raising awareness of HPV. Through this annual campaign IPVS aims to promote progress on HPV prevention, screening and management of HPV related diseases.

Health Breaking News: Link 286

Health Breaking News Links, as part of the research project PEAH (Policies for Equitable Access to Health), aim to focus on the latest challenges by trade and governments rules to equitable access to health in resource-limited settings

Health Breaking News: Link 286

 

Improving Individual And Community Health Through Better Employment Opportunities 

When We Build The Next Health System, Can We Break The Cycle Of High Costs And Low Value? 

The next forum for unraveling FDA off-label marketing rules: State and federal legislatures  

IFIC webinar: Integrated Care Matters Series 2: A Community Approach to Palliative and End of Life Care 16th May, 2018 12.00 – 13.00 (BST) 

Ongoing training of community health workers in low-income and middle-income countries: a systematic scoping review of the literature 

Development Cooperation Has Emerged a Winner in the EU’s 2021-2027 Budget Proposal, but the Odds Are Stacked against It 

Open letter to the EU on the use of ODA to support private investments in developing countries 

IMF conditionality: still undermining healthcare & social protection? 

Dept. of Renewal: A Pharma Foundation Keeps the Money Flowing to Its Global Health Grantees 

UN forum to coordinate global efforts to address worsening water shortages 

Recipe to Save 700,000 Young Children a Year: Clean Water & Decent Toilets 

A Simple Way to Improve a Billion Lives: Eyeglasses 

Global Health: Chatham House Round-Table Re-Defines Development Of Bio-Safety Labs In Developing Countries 

MSF: Access Campaign Year in Review 2017 

Unitaid Calls For Proposals On TB, Hails New Insecticide 

Against all odds, Yemen launches its first large-scale treatment campaign against trachoma  

(S)WASH-D for Worms: A pilot study investigating the differential impact of school- versus community-based integrated control programs for soil-transmitted helminths 

Collective Efforts By Civil Society Groups Bar The Way To Hepatitis C Patents  

Ebola: DR Congo confirms new outbreak in country’s north-west 

UK joins Ebola fightback as four more cases are reported  

Lesotho HIV and health situation room brings innovation to country’s AIDS response 

AIDS Runs Rampant in Venezuela, Putting an Ancient Culture at Risk

Truvada Case Shows Civil Society’s Success With Pre-Grant Opposition 

Evergreened Patents Cause Unwarranted High Drug Prices, Hinder Growth Of Local Producers – NGOs, Thai Producers Claim 

Brazilian Superior Court Of Justice Stops Patent Term Extension Attempts  

Study Finds Rise In Use Of India’s Section 3(d) Against Pharma Primary Patents 

US State-By-State Analysis Shows Benefits Of Funding Global Health Research 

Fast Forward: How the Trump Effect is Accelerating Key Trends in Philanthropy 

Nicaragua: the House of Cards you probably didn’t notice 

HMONG May 2018 Newsletter 

Human Rights Reader 446 

Safeguards against sexual exploitation and abuse in development and humanitarian action – European NGOs action points  

The Green Climate Fund commits billions, but falls short on disbursements 

Education key to Pakistan reducing carbon emissions 

NGOs tell Commission to listen to science and differentiate biofuels 

Waste in Medical Research Threatens SDG Health Targets

The negative effects of incomplete registration and reporting of clinical trials go far beyond the wasteful duplication of research efforts. Opacity in clinical trials also slows down the discovery of new treatments and cures. In addition, selective reporting of trial results tends to make new and more expensive drugs look more effective than cheaper generic alternatives, leading to the misallocation of scarce public health funds, including in developing countries

By Till Bruckner

Founder of TranspariMED

Governments’ Failure to Curb Rampant Waste in Medical Research Threatens SDG Health Targets

 

Most major medical research funders are still failing to curb research waste, slowing down medical progress and threatening the attainment of several of the Sustainable Development Goalshealth targets, a new study shows.

Published in JAMA in April 2018, the study led by Nicholas DeVito of the University of Oxford shows that many of the world’s largest public and philanthropic funders have failed to put into place basic safeguards to ensure that the results of the clinical trials they fund contribute to scientific progress and global health, with public funders in China, France, Italy, and Spain performing particularly poorly.

Around half of all clinical trials conducted worldwide do not report their results, and hence make no contribution whatsoever to the global search for new treatments and cures. As a result, an estimated $85 billion invested into medical research go to waste every year. For example, a recent search of the U.S. government run registry Clinicaltrials.gov conducted by TranspariMED identified 494 completed clinical trials of potential vaccines for HIV, tuberculosis and malaria. Out of those, 82% had not posted summary results onto the registry, contrary to best practices set out by the World Health Organization. The proportion of these trials that have additionally failed to publish results in the academic literature is unknown.

For the new study, the team in Oxford selected the top 20 non-commercial funders of health research globally and examined their policies on clinical trial transparency and research waste. (Between them, these funders spent $41 billion on health care research in 2013 alone.)

Only four of the twenty top funders, Britain’s National Institute for Health Research (NIHR), Germany’s Deutsche Forschungsgemeinschaft (DFG), the European Union’s Horizon 2020 programme, and the United States’ National Institutes of Health (NIH), earned full marks for demanding that all trials they fund are registered and their results reported, and for ensuring grantees’ compliance with these rules through audits.

In contrast, public research funders in China, France (CNRS and Inserm), Italy (Ministry of Health), and Spain (ISCIII) had not even put related policies onto paper, let alone taken steps to ensure that they were followed in practice.

Which Funders Ensure that Clinical Trials are Registered and Reported?

Note: A funder is counted as ensuring that trials are registered and/or reported only if it has a relevant policy and audits grantees’ compliance. Table adapted from DeVito et al (2018). Countries highlighted in yellow have a mixed performance.

The performance of major philanthropic funders was also disappointing. At the time they were assessed, in spring 2017, neither the Gates Foundation nor the Wellcome Trust required their grantees to share the results of their research. Both organizations have since pledged to strengthen their policies and conduct regular audits of their grantees’ performance.

Clinical trials are the cornerstone of modern medicine. The negative effects of incomplete registration and reporting of clinical trials go far beyond the wasteful duplication of research efforts. For example, it can leave potential harms undetected; over 100,000 patient deaths in the United States alone have been directly linked to weak clinical trial transparency.
Opacity in clinical trials also slows down the discovery of new treatments and cures. In West Africa, efforts to contain the Ebola epidemic foundered because the results of many Ebola trials remained unknown. Unless research funders fix the system and speed up results sharing, the Sustainable Development Goals’ targets of supporting the development of new vaccines and medicines, and of ending the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases by 2030, are unlikely to be achieved.

In addition, selective reporting of trial results tends to make new and more expensive drugs look more effective than cheaper generic alternatives, leading to the misallocation of scarce public health funds, including in developing countries. For example, governments worldwide spent billions on the drug Tamiflu based on partial trial data, only to discover later that the drug was largely ineffective. Clearly, the Sustainable Development Goals’ target of “access to safe, effective, quality and affordable essential medicines and vaccines for all” cannot be achieved as long as health officials cannot even determine whether a given drug is safe or effective, let alone whether it is cost-effective compared to other treatments.

For this reason, a coalition of health integrity groups led by Transparency International recently called on governments worldwide to take decisive action to make clinical trials transparent. “In future, to help ensure that public funding for medical research actually benefits the public, government funders should only give taxpayers’ money to institutions and individuals that verifiably comply with best practices in clinical research,” the global anti-corruption group recommended. “Taking this simple first step would deliver significant transparency gains at minimal cost.”

As the transparency pioneers in Britain, Germany and the United States demonstrate, this is entirely feasible. The next step will be for global health advocates, scientists and taxpayers in Australia, China, France, Italy, and Spain to ask their politicians why they are still allowing public funds to be wasted on clinical trials that fail to adhere to global transparency norms.

 

AUTHOR BIO

Till Bruckner (tillbruckner@gmail.com) is the founder of TranspariMED, a campaign that works to end evidence distortion in medicine. He previously worked for the AllTrials campaign and the anti-corruption group Transparency International. He remains active with Transparify, an initiative to promote transparency and integrity in policy research and advocacy. In his previous life, he worked in international development, occupying both field and research roles. Till holds a PhD in political science from the University of Bristol, U.K.  

 

 

 

 

Health Breaking News: Link 285

Health Breaking News Links, as part of the research project PEAH (Policies for Equitable Access to Health), aim to focus on the latest challenges by trade and governments rules to equitable access to health in resource-limited settings

Health Breaking News: Link 285

 

EU budget battle kicks off amid single instrument concerns 

EU budget breakdown: What you need to know 

Health deserves more, not less spending! | EPF-EPHA Joint Statement 

Budget downgrades EU aid policy, say development experts 

Impact of the European Convention on Human Rights 

USTR Priority Watch List calls out countries for protecting public health 

WHO donors in 2017 – US, Gates Foundation, UK, World Bank, GAVI, Germany and the European Commission: Setting the Agenda for Global Health? 

UNPO April 2018 newsletter 

A Health Funder Puts Women of Color Front and Center of Latest Work 

Maternal mortality in Asia-Pacific – 5 key facts 

From surviving to thriving: What evidence is needed to move early child-development interventions to scale? 

World Day for Safety and Health at Work 

Digital health in South Africa: innovating to improve health  

Grants to Tackle a Difficult—But Unavoidable—Issue: End-of-Life Care 

Mounting Debt Threatens Sustainable Development Goals 

Why corruption thrives at the local level: insights from Bangladesh and Nigeria 

Africa’s alternative path to development  

Big sugar and the ‘big flaw’ in Australia’s federal health programs 

What are the political drivers for GMOs in developing countries? 

Metropolis 2020: on the Way to 90-90-90 

The long and expensive fight to eradicate polio 

It’s (Past) Time We Prepare for the Next Pandemic 

Stepping up European action on vaccine-preventable diseases 

AI dengue prediction tool trialled in Asia, Latin America  

Ukraine Eyes Patent Law Reform After Civil Society Push On Medicines Access 

Patents Without Examination: A Bad Solution For The 21st Century 

Civil Society of Kyrgyzstan in the Fight for Availability and Affordability of Medicines

Civil Society Key In TRIPS Flexibility Implementation 

The Economist comes out in support of Universal Health Care – here are the best bits  

Climate change aid to poor nations lags behind Paris pledges 

9 out of 10 people worldwide breathe polluted air, but more countries are taking action 

Exposure to carcinogens at work in EU’s crosshairs 

Weak policies harming circular economy path in Africa 

GGGI assesses inclusive green development Belt and Road opportunities  

The new CAP: great promise or give-away? Notes on the leaked proposal 

 

Fair Research Partnerships in European Commission Funded Research

The EU is clearly not the only research funder that struggles with ‘partnerships’ – in fact, we are not aware of any widely accepted framework related to effectiveness, efficiency, impact or ‘fairness’ of research partnerships anywhere. There is also no systematic learning happening – we are not sharing best practices – we are not learning what happens in other parts of the world.

In response, COHRED has developed the Research Fairness Initiative (RFI)  aimed at creating a due diligence instrument and compliance tool for exactly this : ensuring that partnerships work and are ‘fair’

By Carel IJsselmuiden, Executive Director

and Kirsty Klipp, Research Fairness Initiative – RFI Implementation Manager

Council on Health Research for Development – COHRED

Fair Research Partnerships in European Commission Funded Research – Do We Know What is Actually Happening with Public Funds?

 

The EU Directorate-General for Research and Innovation (DG-RTD) is responsible for EU policy and action on research and innovation aiming at making the EU globally competitive, creating jobs and economic growth, building EU-wide research infrastructure, tackling the big societal challenges, and supporting general EC’s mission to promote justice and human rights and become a global actor.

That is quite a portfolio. Commensurate to the task, the resources available for achieving the mission and strategies of the DG-RTD are substantial. The Horizon 20/20 programme alone already has more than €70 billion allocated to it. With all types of added special funds and special interests of member states, the total is certainly much higher.

In the context of pursuit of justice and of Europe as a global actor, special programmes such as the EDCTP (European and Developing Country Clinical Trials Programme)  add substantially to the total funds available to low and middle income countries to help build their research and innovation systems and resilience. Similar aims within Europe are pursued with programmes like WIDESPREAD that aim to bring ‘underperforming’ EU and Associated countries to a higher level of research performance.

Irrespective of the specific focus of programme – almost all EU funded research programmes and research calls aim for two specific outcomes. Firstly, improvement in knowledge and understanding – advancing specific scientific fields that have been prioritized by the DG-RTD.

The second focus, although implied and hardly visible but nevertheless a cornerstone of any EU funding, is to bring EU institutions together in research partnerships: within the EU to improve the research and innovation infrastructure within the EU, and with external countries to either access expertise needed to make EU more globally competitive (in case of collaboration with high-income countries) or to support low and middle income countries to build up their own research and innovation systems and become more economically resilient.

In brief – EU funded research focuses on specific scientific advancement and on supporting institutional research partnerships.

The first – specific scientific advancement – is well measured.  DG-RTD holds EU wide consultations, involves citizens, pays consultants, holds meeting – and, above all, has an extensive metric with which to assess cutting edge research, researchers and research institutions. This metric is based on globally acceptable standards and on EU developed criteria that are well worked out, public and made obligatory for reviewers in judging proposals for funding submitted in response to research calls by the DG-RTD. So far, no problem.

It is the second one where problems appear – supporting institutional research partnerships. A short view on the H2020 call page today (25 April 2018) shows long lists of calls – almost everyone has ‘collaboration’, ‘partners’, ‘joint’, ‘regional’, and more expressions showing the centrality of partnership to achieving research and innovation goals.

Yet, there is hardly any criteria by which to measure impact nor with which to equip reviewers of calls to make informed and transparent selection of applications successful in this second core aspect of EU calls.

The best summary is informal. We have ‘discovered’ 3 criteria – one of which is ‘hard’ but largely meaningless, and the other 2 cannot really be objectively interpreted, and seem to run against reality.

Criteria 1 – if the call specifies a certain number of partners, then the check is simple. Meets or does not meet. Very objective and very accurate, but hardly of any relevance to the goal.

Criteria 2 and 3 – focus on ‘approximate similar budgets’ and ‘approximately similar responsibilities’ to safeguard against calls serving only one or a few institutions where the others are added pro-forma. This may be especially important in joint research with low and middle income institutions and reduces the massive resource imbalance between partners. However, it is not clear how this rewards partnerships where some partners really have higher expertise, equipment, facilities whereas others are just starting. There is no ‘right figure’ for ‘approximately similar budget’ or ‘approximately similar responsibility’ – and, in fact, this is not a criteria which reviewers can reasonably use transparently. The EU can also not really measure impact of the partnership component – for example in achieving competitiveness, or in achieving research system building in low and middle income countries.

The EU is clearly not the only research funder that struggles with ‘partnerships’ – in fact, we are not aware of any widely accepted framework related to effectiveness, efficiency, impact or ‘fairness’ of research partnerships anywhere. There is also no systematic learning happening – we are not sharing best practices – we are not learning what happens in other parts of the world. It seems that science has deserted its own core – there is no systematic study and learning of the second pillar of successful and competitive science infrastructure: partnerships.

In response, the Council on Health Research for Development – COHRED has developed the Research Fairness Initiative (RFI) aimed at creating a due diligence instrument and compliance tool for exactly this: ensuring that partnerships work and are ‘fair’.

Essentially, the RFI proposes a global reporting system for academic and research institutions, government agencies, research funders and business engaged in research – in fact, it is applicable to all key stakeholders in global (health) research. The RFI Report is written around pragmatic and universally applicable indicators of the quality and fairness of research collaborations. Originally aimed at research collaborations that involved low and middle income countries, it is now clear that it applies across sciences and across socio-economic strata of countries.

The concept is simple: every institution prepares their own RFI Report once every two years. The report consists of the answers to a series of questions focusing on the quality, fairness and equitability of research collaborations. The questions are simple – the answers are usually simple – but action to improve may be intensive : i) what is your institution’s current policy or practice related to … ; ii) if you have examples of good policies and practices, please share this, and iii) what improvements are envisaged in the short term. This is repeated for 15 key topics – each assessed by 3 indicators.

This will achieve transparency in how research partnerships are set up and managed, create a pool of shared practices and systematic learning from which new standards and benchmarks can be developed.

There is no doubt that institutions at the beginning of the research excellence curve need international partnerships to develop their science base further – and there is also no doubt that many of the current partnerships are far from optimal these institutions – for example, in terms of sharing intellectual property, authorship, data ownership, decision making, and access to funding – all issues that the RFI requests answers to.

A first RFI Report has been published now by the Tropical Disease Research and Training Programme of the WHO (WHO/TDR). This enables you to see how the RFI works, what an RFI Report can look like. The RFI Reports of three Senegalese institutions and of the Institute of Tropical Medicine and Hygiene of the New University of Lisbon are nearing completion. Others are in the pipeline.

It is time that one of the world’s biggest research funders begins to focus seriously on improving metrics, transparency and impact of the thousands of partnerships it promotes and supports through its funding by adopting the RFI as a key due diligence tool – that is readily available, increasingly used and creates the first systematic learning platform for improved research and innovation partnerships.

Why not insist that a lead organization in any EU funded partnership submits their own institutional Research Fairness Initiative Report as evidence that it has thought seriously about 15 of the most frequently mentioned aspects that make or break partnerships?

Surely – €70+ billion in partnership funding requires such a tool.

 

 

 

 

 

 

Health Breaking News: Link 284

Health Breaking News Links, as part of the research project PEAH (Policies for Equitable Access to Health), aim to focus on the latest challenges by trade and governments rules to equitable access to health in resource-limited settings

Health Breaking News: Link 284

 

At development financing forum, top UN officials urge breakaway from ‘short-termism’ 

The EU must put poverty reduction before corporate profits when financing development 

Will the UK Labour Party’s Big Idea of an Inequality Target Help or Hinder Development? 

The origins of global institutions and development May 2, 2018 12:15 PM – 2:00 PM, Auditorium 3, Eilert Sundts hus, Oslo 

Time for EU to take charge of global health research agenda 

ENSURING PUBLIC ACCOUNTABILITY AND SOCIETAL IMPACT, PRIORITISING GLOBAL CHALLENGES IN FP9: REACTION TO THE LEAKED FP9 IMPACT ASSESSMENT 

2018 IMF and World Bank Spring Meetings: the Bank has more money, but promises little change 

5 takeaways from the World Bank Spring Meetings 

A new type of leadership from national governments is essential for success of the SDGs 

Some examples of South Africa’s global and regional health diplomacy in the SDG health era  

Homegrown Help: The Rise of Africa’s New Philanthropists 

Trends in tuberculosis in the UK 

A cluster of multidrug-resistant Mycobacterium tuberculosis among patients arriving in Europe from the Horn of Africa: a molecular epidemiological study, TM Walker et al, Lancet Infectious Disease April 2018 

World Malaria Day, 25 April 2018 

On World Malaria Day: thinking and acting locally for global malaria elimination 

The clock is ticking on malaria 

Beating Malaria in Zambia 

World Immunization Week, 24-30 April 2018 

The evidence around vaccines – fact vs. myth 

How immunisation is vital to win the war against disease 

Point-of-care tests for syphilis and yaws in a low-income setting – A qualitative study of healthcare worker and patient experiences 

World Meningitis Day: 5 Questions with the CEO of NCDC 

The Belgian commitment to pharmaceutical quality: a model policy to improve quality assurance of medicines available through humanitarian and development programs 

Infant Deaths Fall Sharply in Africa With Routine Antibiotics 

Interpol Highlights Takedown Of Deadly Global Fake Food And Drink Operations  

Could violent conflict derail the London Declaration on NTDs?  

New publication calls for urgent action on energy to achieve Global Goals 

How Integrating Health Care With Other Services Offers Significant Potential Benefits 

The Alternatives – approaches towards a Life in Full 

The Alternatives: Global perspectives for healthier lives 

Human rights Reader 445 

TIME 100’s Nice Nailantei Leng’ete Honors the People Working to End Female Genital Mutilation 

USA: New Dangers For Immigrants And The Health Care System 

 

Quality-Assurance of Medicines in Humanitarian and Dev Programs: A Proposal from Belgium

A “Commitment to Quality Assurance for Pharmaceutical Products” was signed in 2017 in Brussels by the Belgian Deputy Prime Minister and Minister for Development Cooperation Alexander De Croo, and by 19 Belgian implementers. With the signature of this policy, the Belgian State commits to manage the quality risks of medicines in the medical programs funded overseas, while the Belgian implementers commit to set up adequate quality assurance systems, and to prove that the medicines they supply are in compliance with the standards of the WHO and International Conference of Harmonization

By Raffaella Ravinetto

Public Health Department, Institute of Tropical Medicine Antwerp, Belgium

Who is Taking Responsibility for the Quality-Assurance of Medicines Supplied in Humanitarian and Development Programs? A Proposal from Belgium

 

Universal access to quality-assured essential medicines is a determinant of the fulfilment of the right to health (1), but unfortunately substandards and falsified medicines still represent a serious concern for global health (2). Recent data of the World Health Organization (WHO) suggest that at least about 10% of medicines available in low- and middle-income countries are of poor quality (3). Their often-undetected consequences include therapeutic failure and direct toxicity; contribution to emerging resistances; and, at health system level, erosion of public trust in medicine, and waste of resources. Medicines regulation is theoretically the responsibility of the National Medicines Regulatory Authorities in the recipient countries, but many under-resourced Agencies in the South lack the financial resources, human resources and infrastructure needed to adequately verify the quality of medicines supplied from the international market (4), which is increasingly complex due to the rampant globalization of production and distribution.

In countries with limited resources and poor regulatory capacities, a great deal of medicines provided through the public sector (and/or during public health emergencies) are funded by external donors and procured by Non-Governmental Organizations (NGOs) and other implementers. The quality of these medicines thus depends, more than on national regulators, on the procurement policies of such donors, NGOs and implementers. This implies a great variability in the level of pharmaceutical quality assurance: while organizations such as Médecins Sans Frontières (5) and the Global Fund (6) have stringent criteria in place, other actors lack procurement policies with adequate quality requirements. This is often due to lack of awareness of the actual risks taken when administering a medicine the quality of which has not been adequately verified: for instance, therapeutic failure due to an under-dosed medicine can be mistakenly attributed to other reasons (e.g. poor adherence, late intervention, wrong diagnosis…). Thus, the victims of poor-quality medicines remain in most cases voiceless.

The case of humanitarian and development programs brings additional moral challenges to this issue, because patients served by these programs should not receive medicines with a quality-assurance level that would not be acceptable in the country of the donor or of the implementer: “there should be no double standard in quality. If the quality of an item is unacceptable in the donor country, it is also unacceptable as a donation” (7).

As an innovative attempt to acknowledge and address these challenges, a “Commitment to Quality Assurance for Pharmaceutical Products” was signed in 2017 in Brussels by the Belgian Deputy Prime Minister and Minister for Development Cooperation Alexander De Croo, and by 19 Belgian implementers (8) (https://www.itg.be/E/Article/belgian-commitment-on-quality-of-medicines-is-unique-says-institute-of-tropical-medicine-antwerp). With the signature of this policy, the Belgian State commits to manage the quality risks of medicines in the medical programs funded overseas, while the Belgian implementers commit to set up adequate quality assurance systems, and to prove that the medicines they supply are in compliance with the standards of the WHO and International Conference of Harmonization. The implementers may integrate a specific budget for pharmaceutical quality assurance in their financing applications, and they should consider how costs “could be rationalized and mutualized by aligning the strengths of the various implementers”. Importantly, to mitigate the risk of weakening the local pharmaceutical supply systems in the countries of intervention, the implementers should prioritize existing local structures for storage and distribution, and they should design adequate plans of capacity building for local actors when needed.

The promoters of the new policy, which will be implemented in a stepwise approach and with ongoing peer-reviews, hope that “more and more policy-makers, implementers and donors become aware that investing in quality assurance results in gains for health (improved quality of care), ethical behavior (no double standards between patients in affluent and poor countries) and even cost-effectiveness (better quality of care means less therapeutic failures, and decreased long-term health costs)”. They also underline that, “if more donors and implementers joined forces in requiring quality-assured products, they would create a “market incentive” to quality that could in the long-term lead to broader availability and lower prices of quality-assured products”.

Acknowledgment

This contribution is based on a paper recently published in the Journal of Pharmaceutical Policy and Practice (https://joppp.biomedcentral.com/): Ravinetto R, Roosen T, Dujardin C. The Belgian commitment to pharmaceutical quality: a model policy to improve quality assurance of medicines available through humanitarian and development programs. Journal of Pharmaceutical Policy and Practice 2018; 11:12: 1-5. Available at https://joppp.biomedcentral.com/articles/10.1186/s40545-018-0136-z   

References

1) Hogerzeil HV. Essential medicines and human rights: what can they learn from each other? Bulletin of the World Health Organization 2006; 84:371-375.

2) World Health Organisation. Substandard and falsified medical products. 70th World Health Assembly; 2017 22-31 May; Geneva, Switzerland [cited 2017 Nov 5]. Available from: http://www.who.int/mediacentre/news/releases/2017/dementia-immunization-refuguees/en/

3) World Health Organization (WHO). WHO Global Surveillance and Monitoring System for substandard and falsified medical products. WHO/EMP/RHT/2017.01. WHO 2017. Geneva, Switzerland.  ISBN: 978-92-4-151342-5

4)  World Health Organisation. Assessment of medicines regulatory systems in sub-Saharan African countries. World Health Organisation, 2010. Last accessed on 11/11/2017 at http://apps.who.int/medicinedocs/en/d/Js17577en/.

5) MSF Medical Product Qualification Scheme. Last accessed on 8/1/18 at http://www.msf.org/en/article/msf-medical-product-procurement

6) Global Fund Policy. Available at  https://www.theglobalfund.org/media/5894/psm_qapharm_policy_en.pdf

7) World Health Organization (WHO). Guidelines for Medicines Donation. WHO, Geneva, Switzerland. Third Edition 2011. ISBN 978 92 4 150198 9

8) Commitment to quality assurance for pharmaceutical products, between the Belgian Development Cooperation and the actors involved in the implementation of programmes including the purchaseing, storage, distribution and/or control of pharmaceutical products. Brussels, Belgium, 25 October 2017. Available at https://diplomatie.belgium.be/nl/Beleid/Ontwikkelingssamenwerking/Wat_doen_we/Thema/Sociale_ontwikkeling/Gezondheid?

 

 

 

 

 

Health Breaking News: Link 283

Health Breaking News Links, as part of the research project PEAH (Policies for Equitable Access to Health), aim to focus on the latest challenges by trade and governments rules to equitable access to health in resource-limited settings

Health Breaking News: Link 283

 

Integrated Care: Your opinion counts! 

Integrated Care Solutions© Webinar: The Implementation Model for Integrated Care 

Thirty-three civil society groups write to Commissioner Malmström expressing concerns over the European Commission’s plans to create an EU Watch List 

A “Gold Standard” For Population Health? Revisiting The FDA’s Relationship With The Hippocratic Oath 

Answering Senator Bill Cassidy’s Questions About Health Care Price Transparency 

Hepatitis C Drugs Can Cost $84,000. This New One May Be Just As Good—But Cost $300 

KEI sues NIH over license of CD30 CAR T patents to Gilead 

Charles Gore, Founder Of World Hepatitis Alliance, To Head Medicines Patent Pool 

Carlos Correa Named Head Of Intergovernmental South Centre 

China unveils int’l development cooperation agency 

2017 development aid figures: A half empty mixed bag  

WHO: public health round-up 

Latest findings on non-communicable diseases: what is happening in Asia and the Pacific? 

China, India lead rise in global antibiotic consumption 

Taking up Africa’s cancer challenge 

UK leads fight to eliminate blindness 

Opinion: African experts warn big changes needed to eliminate malaria 

Commonwealth Leaders to halve malaria by 2023

The Nigeria Centre for Disease Control 

Unveiling vaccine hesitancy in the Federation of Bosnia and Herzegovina 

PLWH Network Launches New Concept Clinics in Ukraine 

HIV in Georgia: is there any stigma

With improvements in child marriage fight, some fear a funding drop 

Expert calls for men’s inclusion in family planning advocacy 

Financial inclusion is improving around the world—but women are still missing out 

UNPO: Thousands of Uyghurs To Protest Against ‘Re-education’ Camps in Brussels on 27 April 2018 Friday 27 April 2018 | 10:00 — 14:00 

Human Rights Reader 444 

Protect indigenous people’s land rights and the whole world will benefit, UN forum declares 

A global campaign to combat ageism 

Cooperation at heart of Africa Climate Week talks 

UN Shipping Agency Endorses First-Ever Target for Slashing Emissions 

Argentina Aims for a Delicate Climate Balance in the G20 

Latin America Faces Uphill Energy Transition 

Europeans will have to recycle half of their waste by 2025

Health Breaking News: Link 282

Health Breaking News Links, as part of the research project PEAH (Policies for Equitable Access to Health), aim to focus on the latest challenges by trade and governments rules to equitable access to health in resource-limited settings

Health Breaking News: Link 282

 

Randall Packard: learning to learn from global health history 

MSF: Open Letter to European Commissioner on EU India Free Trade Agreement and its impact on access to medicines 

MSF statement on resumption of EU-India FTA negotiations  

7 April 2018: Launch of the campaign: One year to say no to the commodification of health! 

Universal health coverage depends on solid data 

How States Rank On A New Summary Population Health Measure Depends On How Important Health Equity Is 

Canada as an SDG role model for High-Income Countries? 

Human Rights Reader 443 

More Mobilization and Impact: Adapting MDB Private Finance Models 

8 Ideas on Reforming the MDBs for the Eminent Persons Group  

Hope For Hepatitis C Patients In Poor Countries – New Affordable Combination With High Cure Rate 

Prevention of mother-to-child transmission of HIV: a cross-sectional study in Malawi 

Gene Editing for Good. How CRISPR Could Transform Global Development  

TDR joins the MIM to mark 20 years of malaria science and collaboration: 7th Pan African Malaria Conference 15-20 April 2017, Dakar, Senegal 

Lancet Commission to develop first-ever roadmap for malaria eradication 

UN-backed campaign to protect nearly a billion people in Africa from yellow fever by 2026 

Study: Global Consumption Of Antibiotics Rising, In Particular In LMICs; Policy Change Needed 

World’s First Case of Drug-Resistant Gonorrhea Highlights the Growing Danger of Antimicrobial Resistance 

Antibiotic stewardship interventions in hospitals in low-and middleincome countries: a systematic review 

Quality of WHO guidelines on snakebite: the neglect continues 

Regulatory evaluation of biosimilars throughout their product life-cycle 

Investing in non-communicable diseases: an estimation of the return on investment for prevention and treatment services 

Noncommunicable disease partnerships and conflicts of interest 

Copenhagen: KEI questions The Lancet Taskforce on NCDs and economics on drug pricing & delinkage  

Penny Mordaunt: five ways the UK can deliver renewed global leadership  

A Grass-Roots Movement For Healthy Soil Spreads Among Farmers 

‘Silent, invisible’ malnutrition seen as threat to generations in Congo 

Multicontaminant air pollution in Chinese cities 

China’s Answer to the World Bank Wants Green, Clean Asian Infrastructure 

UN urges developing nations to incorporate climate change in urban planning 

Health Breaking News: Link 281

Health Breaking News Links, as part of the research project PEAH (Policies for Equitable Access to Health), aim to focus on the latest challenges by trade and governments rules to equitable access to health in resource-limited settings

Health Breaking News: Link 281

 

Optimism meets realism: the politics of technology and innovation in global health security 

Accountability and strong laws are key to effective tax collection in Africa 

What’s Happening to the World Income Distribution? 

China’s Grand Idea For The 21st Century: Will The New Silk Road Transform Global Health Assistance?

With New Spending Bill, Congress Steers Foreign Assistance Away from Deep Cuts 

The Medicaid Access Proposed Rule Would Undermine Access, Not Promote It 

2018: USTR report chastises India for “vocal encouragement and propagation” of policies that erode IPRs 

‘Policy Implications for Community-based Interventions to Strengthen Healthcare Delivery, Based Upon a Formative Study of Community Capacity in Urban Monrovia, Liberia’ Corresponding Author Richard A. Nisbett 

Lessons from Liberia with Ellen Johnson Sirleaf – CGD Podcast 

‘The alarming collapse of the Venezuelan healthcare system’ by Pietro Dionisio  

The End of Antibiotics? 

Research suggests gonorrhoea can resist last-resort antibiotics and maintain growth rate 

What are the strategies to make 2018 the year for TB action? 

Unitaid’s investments support global drive to end TB 

Tuberculosis services in Moscow extend “health for all” even to the most vulnerable  

Il Sole24Ore: Tubercolosi, immigrazione e Italia. Tutti i numeri 

REVEALING THE NEGLECT: RIVER BLINDNESS 

Shedding Some Light on Skin Cancer in Tanzania 

TogetHER: Working Together to Save Women from Cervical Cancer  

Integration of postpartum healthcare services for HIV-infected women and their infants in South Africa: A randomised controlled trial 

Major Study Finds Taxes On Soda, Alcohol, Tobacco Help Curb NCDs; Study Restarts UN Momentum  

A New Way to Finance Green City Projects, With a Boost From Foundations 

Wind of change: Air and Health in 2019 

Study counts lives saved with push for 1.50C climate target 

Not enough done at EU level against imported deforestation 

“It Takes Time.” In Africa, a Test of Philanthropy’s Quest to Bring Safe Water to All 

World Bank Group report: Women, Business and the Law 2018 

Webinar: Integrated Care Matters Series 2: District Nursing, Case Management & Buurtzorg Model 18th April, 2018 12.00 – 13.00 (GMT) 

How an uproar over aid and sexual exploitation ignored women’s actual experiences 

UNPO Newsletter March 2018 edition 

PRESS RELEASE – 7 April: European action day against the commodification of health « All for Health » 

Map of the 7 April 2018 actions 

Human Rights Reader 442